Statistical analyses
Assuming an ORR of 35%, 26 patients were estimated to provide the phase II study with a probability of >80% to detect an ORR of ≥26.5% (the lower limit of the 95% confidence interval [CI] for ORR in the FIGHT‐202 trialEfficacy endpoints were analyzed primarily in the efficacy‐evaluable population (EEP), which included patients with centrally confirmed Data were summarized using descriptive statistics. The 95% CIs for ORR and DCR were estimated using the Clopper‐Pearson method. Time‐to‐event data were analyzed using the Kaplan–Meier method. The frequency of 